Lumateperone not checked

Intra-Cellular Therapies, Inc. · ITI-007

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
6 active
23 in total · 3 in the EU

What this is

How it works
Atypical Antipsychotic FDA class
How it’s given
“Lumateperone 5 mg - 42 mg capsules or orally disintegrating tablets administered orally, once daily based on age and indication”In the company’s words, NCT06229210 on ClinicalTrials.gov
Tested for
Irritability Associated With Autism Spectrum Disorder (2 trials), Major Depressive Disorder, Depressive Disorder, Major, Bipolar Depression, Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder
Main trialPhase 3
“This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.”In the company’s words, NCT05850689 on ClinicalTrials.gov
Other names
Caplyta · ITI-007

Other drugs for Irritability Associated With Autism Spectrum Disorder

All 10 drugs for Irritability Associated With Autism Spectrum Disorder

Coming up6

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials23

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 5 Apr 2027 Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Phase 3Recruiting 21 Jun 2027 Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients
Phase 3Recruiting 21 Jun 2027 Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients
Phase 3Not yet recruiting 20 Sep 2029 A Study of Lumateperone Versus Placebo in Participants With Major Depressive Disorder
Phase 3Recruiting 31 Oct 2031 Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
Phase 3Recruiting 28 Apr 2032 Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
Phase 3Completed Jul 2015 A Trial to Assess the Antipsychotic Efficacy of ITI-007
Phase 3Completed Aug 2016 A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment
Phase 3Completed 28 Jan 2019 Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression
Phase 3Terminated 30 Jan 2019 ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease
Phase 3Completed 1 Mar 2019 Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally
Phase 3Completed 2 Jul 2020 Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression
Phase 3Completed 30 Nov 2022 Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder
Phase 3Completed 22 Feb 2024 Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Phase 3Completed 12 Apr 2024 Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Phase 3Completed 25 Jul 2024 Lumateperone for the Prevention of Relapse in Patients With Schizophrenia
Phase 3Completed 14 Oct 2024 An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Phase 3Completed 24 Feb 2026 Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania
Phase 3Completed 15 May 2026 Study of Lumateperone in the Treatment of Patients With Bipolar Mania
Phase 2Completed Aug 2013 Study of a Novel Antipsychotic ITI-007 in Schizophrenia
Phase 1Completed 30 Jul 2022 Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder
Phase 1Completed 20 Nov 2025 Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder
Phase 1Completed 26 Nov 2025 Safety, Tolerability and Pharmacokinetics of Lumateperone in Pediatric Patients With Autism Spectrum Disorder
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Lumateperone

Following is part of Solo: you see every change to Lumateperone the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in